Information and recommendations for approved bodies on the presentation and review of a periodic safety update report (PSUR).
Similar Posts
National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Quetiapine Oral Suspension (unlicensed medicine), manufactured by Eaststone Limited due to a potential for overdosing, NatPSA/2026/002/MHRA
Eaststone Limited is initiating a recall of all batches of quetiapine oral suspension products due to a potential risk of overdose, which could have consequences for the safety of patients.
Field Safety Notices: 28 July to 1 August 2025
List of Field Safety Notices from 28 July to 1 August 2025.
Field Safety Notices: 22 to 26 September 2025
List of Field Safety Notices from 22 to 26 September 2025.
Decentralised Manufacture: Labelling
Guidance on labelling requirements pertinent to the type of medicinal product and its supply status, as defined in UK legislation.
Class 4 Medicines Defect Notification: Dulcolax Adult 5 mg Gastro-resistant Tablets, Opella Healthcare UK, EL(25)A/26
Opella Healthcare UK LTD has informed the MHRA that there is an error on the artwork for the outer carton of Dulcolax Adult 5mg GR Tablets (packsize 20 count). The dose instruction incorrectly states for use in 12 years and older. These general sale packs are intended for use only in adult patients (18 years and over).
AI breakthroughs drive expansion of ‘Airlock’ testing programme to support AI-powered healthcare innovation
MHRA opens second round of applications to test cutting-edge AI medical technologies following successful pilot phase.